AVICANNA INC

Avicanna Inc. pioneers cannabinoid‑based drugs, blending scientific innovation with diverse consumer, medical and pharma markets—investors eye its growing pipeline and future potential.

Avicanna Inc. has reported its first profitable quarter in Q1 2025, with revenue of $6.32 million and net income of $74,154, driven by strategic cost efficiencies and margin improvements.

Avicanna Inc. has reported its first profitable quarter in Q1 2025, with a net income of $74,154 and revenue of $6.32 million, driven by cost efficiencies and margin improvements.

Avicanna Inc. has achieved its first profitable quarter in Q1 2025, marking a significant milestone for the Toronto-based biopharmaceutical company and positioning it for sustained growth and innovation in the cannabinoid market.